Other substances

Heparin

A glycosaminoglycan anticoagulant.

Phase of research

Potential treatment - clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

12
 Supporting references
0
 Contradictory references
144
 AI-suggested references
44
 Clinical trials

General information

Heparin is a natural glycosaminoglycan polymer rich in sulphur with molecular weights ranging from 3000 to 30,000 Da. This anticoagulant is released from mast cells. Heparin action is facilitated via antithrombin III binding, which modifies its activity (DrugBank).

Heparin on PubChem
Heparin on Wikipedia

Marketed as

HEPARIN SODIUM; HEPARIN LEO

 

Supporting references

Link Tested on Impact factor Notes Publication date
Increased plasma heparanase activity in COVID-19 patients
Preprint 		Patients

prophylactic use of low molecular weight heparin

 Jun/15/2020
Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line
Spike protein Preprint 		RT4 and A549 cell line May/21/2020
The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding
Preprint 		in vitro Mar/02/2020
The association between treatment with heparin and survival in patients with Covid-19
Patients 2.05

association between heparin and lower mortality

 May/31/2020
Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives
Polysaccharide In vitro 		HEK293T cells 4.37

Inhibits infection by a SARS-CoV-2 spike protein-pseudotyped lentivirus in vitro.

 Nov/10/2020
Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin.
Spike protein Preprint 		VERO cells

addition of heparin (100 μg.ml-1) to Vero cells inhibits invasion by SARS-CoV-2 by 70%

 Apr/28/2020
SARS-CoV-2 Spike S1 Receptor Binding Domain undergoes Conformational Change upon Interaction with Low Molecular Weight Heparins.
Spike protein Preprint 		in vitro Apr/29/2020
Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients
Preprint 		Patients Jun/03/2020
Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19
Polysaccharide In vitro 		Vero E6 cells 1.88

Heparin inhibits SARS-CoV-2 infection in vitro (IC50 < 125 μg/ml in Vero E6 cells).

 Aug/30/2020
Unfractionated heparin inhibits live wild‐type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations
Biophysical assay Polysaccharide In vitro 		in vitro biophysical assay; Vero E6 cells; SARS‐CoV‐2 (Australia/VIC01/2020) 7.73

Unfractioned heparin destabilizes the SARS-CoV-2 spike protein RBD and directly inhibits its binding to host ACE2 receptor in vitro. It also manifests antiviral activity in cell culture.

 Oct/30/2020
Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro
Polysaccharide Small molecule In vitro 		ACE2-GFP HEK293T cells; Calu-3 cells; Vero E6 cells; SARS-CoV-2 pseudotyped particles 6.26

Reduces SARS-CoV-2 pseudovirus cell entry in ACE2-GFP HEK293T cells and Calu-3 cells.

 Nov/04/2020
Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial
Polysaccharide Phase III clinical trial Randomized controlled double-blind trial 		Invasive mechanical ventilation non-COVID-19 patients 25.09

In non-COVID-19 patients with or at risk of ARDS, nebulised heparin did not improve self-assessed physical performance score; however, it was well tolerated and possibly decreased the probability of disease progression and granted earlier hospital discharge. This observation could serve as a model for COVID-19 patients. Sample size: 128 + 124 control. Dosage: Nebulised 25,000 IU every 6 hours. Endpoint: Clinical score at day 60 (primary).



 Jan/22/2021

AI-suggested references

Link Publication date
Hydroxychloroquine shortened hospital stay and reduced intensive care unit admissions in hospitalized COVID-19 patients.
Jan/31/2022
Early treatment with low-molecular-weight heparin reduces mortality rate in SARS-CoV-2 patients.
Oct/26/2021
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
Jan/07/2022
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.
Apr/27/2020
Monoclonal and oligoclonal anti-Platelet Factor 4 antibodies mediate VITT.
May/14/2022
Rationale and design of a study to assess the safety and efficacy of rNAPc2 in COVID-19: the Phase 2b ASPEN-COVID-19 trial.
Jun/28/2021
Comparison of standard prophylactic and preemptive therapeutic low molecular weight heparin treatments in hospitalized patients with COVID-19.
Apr/30/2020
Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial.
Feb/24/2022
Low molecular weight heparin reduces arterial blood lactic acid content and increases estimated glomerular filtration rate in patients with moderate Covid-19 pneumonia.
Mar/20/2022
Add-on Prostaglandin E1 in Venovenous Extracorporeal Membrane Oxygenation: A Randomized, Double-blind, Placebo-controlled Pilot Trial.
Apr/16/2022
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
May/28/2021
In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
Dec/01/2020
Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Feb/20/2021
Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding.
Mar/23/2022
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
Jun/18/2020
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study.
Feb/28/2021
Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study.
Oct/02/2020
The biomaterial polyphosphate blocks stoichiometric binding of the SARS-CoV-2 S-protein to the cellular ACE2 receptor.
Oct/14/2020
Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVID-19: A multicentre case series of 98 patients.
Jan/19/2022
Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19.
Oct/02/2020
Therapeutic vs. prophylactic bemiparin in hospitalized patients with non-severe COVID-19 (BEMICOP): an open-label, multicenter, randomized trial.
Jan/31/2021
In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
Sep/02/2020
Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Dec/30/2021
Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia.
Feb/19/2021
The effects of systemic anticancer treatment (SACT) or radiotherapy on risk of severe illness or death in patients with cancer and COVID-19: Rapid evidence review
Dec/23/2021
The effectiveness of early anticoagulant treatment in Covid-19 patients.
Mar/31/2022
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Oct/22/2020
Effect of Sulodexide on Circulating Blood Cells in Patients with Mild COVID-19.
Mar/08/2022
Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.
Dec/03/2020
Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.
Dec/14/2020
Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries
Dec/03/2021
Unique Mode of Antiviral Action of a Marine Alkaloid against Ebola Virus and SARS-CoV-2
Mar/25/2022
The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms
Dec/18/2021
Surface Glycan Modification of Cellular Nanosponges to Promote SARS-CoV-2 Inhibition
Oct/14/2021
Anticoagulation therapy using unfractionated heparin at a therapeutic dose for coronavirus disease 2019 patients with severe pneumonia: a retrospective historical control study.
Jun/30/2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events.
Jul/01/2021
Impact of low molecular weight heparin administration on the clinical course of the COVID-19 disease
Feb/11/2021
Thrombolysis and use of argatroban for the treatment of massive pulmonary embolism following anticoagulation failure in a patient with COVID-19
Dec/08/2020
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Nov/18/2021
Enoxaparin and Pentosan Polysulfate Bind to the SARS-CoV-2 Spike Protein and Human ACE2 Receptor, Inhibiting Vero Cell Infection
May/12/2021
Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer
Nov/18/2021
Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19
Oct/10/2020
Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions**
Jun/11/2020
Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study
Jan/25/2021
Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection
Jan/14/2021
ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin.
Jun/07/2021
Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.
Mar/27/2021
Therapeutic potential of anticoagulant therapy in association with cytokine storm inhibition in severe cases of COVID-19: A case report.
Aug/23/2021
Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients
May/14/2021
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.
Nov/23/2020
The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.
Apr/23/2021
Anti-SARS-CoV-2 Activity of Rhamnan Sulfate from Monostroma nitidum
Nov/30/2021
Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples
Feb/02/2022
Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients.
Mar/09/2021
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.
Sep/14/2020
The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
Apr/06/2021
Enhanced Antiviral Function of Magnesium Chloride-Modified Heparin on a Broad Spectrum of Viruses.
Sep/17/2021
Time-course analysis reveals that corticosteroids resuscitate diminished CD8+ T cells in COVID-19: a retrospective cohort study
Jun/24/2020
Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin
Dec/23/2020
Marine Sulfated Polysaccharides as Promising Antiviral Agents: A Comprehensive Report and Modeling Study Focusing on SARS CoV-2
Jul/22/2021
Potential Anti-SARS-CoV-2 Activity of Pentosan Polysulfate and Mucopolysaccharide Polysulfate
Feb/21/2022
Molecular Mechanism of the Anti-Inflammatory Action of Heparin
Oct/03/2021
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
Jan/01/2021
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia
Nov/01/2021
Enhanced platelet inhibition treatment improves hypoxemia in patients with severe Covid-19 and hypercoagulability. A case control, proof of concept study
May/23/2020
Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain.
May/04/2021
Early Outcomes of Bivalirudin Therapy for Thrombotic Thrombocytopenia and Cerebral Venous Sinus Thrombosis After Ad26.COV2.S Vaccination
Jul/03/2021
Inactivated SARS-CoV-2 vaccine does not influence the profile of prothrombotic antibody nor increase the risk of thrombosis in a prospective Chinese cohort.
Jul/27/2021
Subcutaneous Enoxaparin Safely Facilitates Bedside Sustained Low-Efficiency Hemodialysis in Hypercoagulopathic Coronavirus Disease 2019 Patients-A Proof-of-Principle Trial.
Jun/15/2020
Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE)
Mar/24/2022
Production of anti-PF4 antibodies in antiphospholipid antibody-positive patients is not affected by COVID-19 vaccination
Sep/02/2022
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19
Mar/01/2021
Fractionation of sulfated galactan from the red alga Botryocladia occidentalis separates its anticoagulant and anti-SARS-CoV-2 properties
Mar/23/2022
A 59-Year-Old Woman with Extensive Deep Vein Thrombosis and Pulmonary Thromboembolism 7 Days Following a First Dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine
Jun/12/2021
Heparin interacts with the main protease of SARS-CoV-2 and inhibits its activity.
Nov/15/2021
Heparan Sulfate Proteoglycans as Attachment Factor for SARS-CoV-2.
Jun/02/2021
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Oct/07/2021
Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019.
Sep/07/2021
The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor
Oct/02/2021
Anticoagulation in Patients With COVID-19
Dec/11/2021
Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19
Jul/09/2021
Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study
Jun/24/2021
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
Jan/08/2021
Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector-based COVID-19 vaccine
Mar/17/2020
A glycosaminoglycan microarray identifies the binding of SARS-CoV-2 spike protein to chondroitin sulfate E
Jun/14/2021
The rationale for using low-molecular weight heparin in the therapy of symptomatic COVID-19 patients
Jan/24/2022
Structural characteristics of Heparan sulfate required for the binding with the virus processing Enzyme Furin
Oct/26/2021
Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking
Apr/08/2021
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study
Oct/15/2020
Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell
Dec/09/2021
Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
Apr/15/2021
Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia
Sep/23/2021
The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients
Sep/12/2020
Renin-angiotensin system modulation and outcomes in patients hospitalized for interstitial SARS-CoV2 pneumonia: a cohort study
Jan/21/2022
Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
Apr/30/2021
SARS-CoV-2 Inhibition by Sulfonated Compounds
Nov/30/2020
Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
Feb/11/2022
Thromboprophylaxis in COVID-19: Weight and severity adjusted intensified dosing
Oct/18/2020
Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
Jun/18/2020
Angiotensin (1-7) peptide replacement therapy with plasma transfusion in COVID-19
Mar/12/2022
Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT
Feb/04/2022
Anti-Platelet Factor 4 Antibodies Causing VITT do not Cross-React with SARS-CoV-2 Spike Protein
Jul/20/2021
Potential mechanisms of nafamostat therapy for severe COVID-19 pneumonia with disseminated intravascular coagulation.
Nov/03/2020
The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
Nov/17/2020
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Feb/24/2022
Case Report of COVID-19 Infection After Kidney Transplant Treated With Casirivimab-Imdevimab and Mycophenolate Mofetil Changed to Everolimus.
Dec/31/2021
Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Jun/04/2021
Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.
Nov/30/2020
Prophylactic anticoagulation with low molecular weight heparin in COVID-19: cohort studies in Denmark and Sweden
Mar/17/2022
Comparison of the Effect of Unfractionated Heparin and Enoxaparin Sodium at Different Doses on the Course of COVID-19-Associated Coagulopathy
May/11/2021
STudy of Alteplase for Respiratory failure in SARS-Cov2 COVID-19 (STARS): A Vanguard Multicenter, Rapidly Adaptive, Pragmatic, Randomized, Controlled Trial
Feb/24/2022
Structural and kinetic analyses of holothurian sulfated glycans suggest potential treatment for SARS-CoV-2 infection
Jan/11/2022
New Heparanase-Inhibiting Triazolo-Thiadiazoles Attenuate Primary Tumor Growth and Metastasis.
Jun/13/2021
Rescue therapy with thrombolysis in patients with severe COVID-19-associated acute respiratory distress syndrome
Feb/19/2021
Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19
Jan/03/2021
Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality
Nov/13/2020
Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
Oct/09/2020
Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia
Sep/15/2021
In silico investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface
Feb/17/2022
STudy of Alteplase for Respiratory failure in SARS-Cov2/COVID-19: Study Design of the Phase IIa STARS Trial.
Aug/19/2020
Severe COVID-19 Pneumonia Treated by Intensive Immune Suppression Therapy With a Combination of Steroid Pulse and Tocilizumab Followed by a Tapering Dose of Steroid Therapy During the Delta (B.1.617.2) Variant Outbreak: A Successfully Treated Case
Nov/07/2021
The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19
May/13/2020
The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.
Sep/24/2020
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions.
Jul/10/2020
An observational study of a cohort of citizens receiving the AZD1222 vaccine against SARS-CoV-2.
Jun/15/2021
Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy
Apr/26/2021
Safety and Pharmacokinetics of Intranasally Administered Heparin
Mar/02/2022
Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19
Mar/23/2022
Beneficial Effects of Anticoagulants on the Clinical Outcomes of COVID-19 Patients.
Nov/13/2021
Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration
Mar/15/2022
Continuous Infusion Low-Dose Unfractionated Heparin for the Management of Hypercoagulability Associated With COVID-19
Oct/14/2020
Safety of intermediate dose of low molecular weight heparin in COVID-19 patients.
Aug/13/2020
Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
Apr/18/2022
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
Jan/03/2022
Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19.
Oct/27/2020
Brief Report - Most Anti-PF4 Antibodies in Vaccine-induced Immune Thrombotic Thrombocytopenia are transient
Apr/02/2022
Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19
May/29/2020
Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components
Sep/10/2020
Coagulopathy, thromboembolic complications, and the use of heparin in COVID-19 pneumonia
Sep/20/2021
Thrombin Inhibition by Argatroban: Potential Therapeutic Benefits in COVID-19.
Sep/01/2020
Low-molecular-weight heparin use in coronavirus disease 2019 is associated with curtailed viral persistence: a retrospective multicentre observational study
Mar/23/2022
Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
Aug/14/2021
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Apr/28/2020
SARS-CoV-2 spike protein causes blood coagulation and thrombosis by competitive binding to heparan sulfate.
Oct/29/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT05255848 Nebulised Heparin in Patients With COVID-19 Pneumonia Not yet recruiting Phase 2|Phase 3 Feb/20/2022 Oct/20/2022
  • Alternative id - 294/LRH/MTI
  • Interventions - Drug: Unfractionated heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Pulmonology Department, Lady Reading Hospital, Peshawar, Peshawar, Khyber Pakhtunkhwa, Pakistan
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 180
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients requiring Intubation|Mortality|Oxygenation|Number of patients showing worsening or improvement on the modified WHO ordinal scale.
NCT05204550 Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children Not yet recruiting Phase 2|Phase 3 Apr/01/2022 Nov/30/2023
  • Alternative id - 83609
  • Interventions - Drug: unfractionated heparin|Drug: 0.9%sodium chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - The Northern Hospital, Epping, Victoria, Australia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1100
  • Age - 5 Years to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - Number of household contacts (swab negative on day 1) testing positive for SARS-CoV-2 by PCR on either of three routine nasopharyngeal swabs on day 3,5 and 10 after enrolment or on nasopharyngeal swab in response to clinical symptoms in the first 14 days|Number of household contacts (swab negative on day 1 of study) becoming symptomatic of COVID-19 in next 28 days|total number of index cases and household contacts (nasopharyngeal swab positive on day 1) combined, who remain swab positive on day 3|total number of index cases and household contacts (nasopharyngeal swab positive on day 1) combined, who remain swab positive on day 5|total number of index cases and household contacts (nasopharyngeal swab positive on day 1) combined, who remain swab positive on day 10|Time to swab negative based on daily anterior nasal swab for index cases and household contacts combined who were swab positive on day 1.|Quantitative replication sub genomic viral RNA at days 3 post randomisation.|Quantitative replication sub genomic viral RNA at days 5 post randomisation.|Quantitative replication sub genomic viral RNA at days 10 post randomisation.|The number of participants who discontinue treatment prior to day 10 from randomisation|Number of index cases and household contacts swab positive on day 1, hospitalized with COVID-19 by day 28 from randomization|Number of household contacts swab negative on day 1, hospitalized with COVID-19 by day 28 from randomization|Maximum severity score of participants (index case and household contacts swab positive on day 1 compared to household contacts swab negative on day 1) during the study period as recorded by daily symptom diary up to day 28|time to symptom resolution analysis for index case and household contacts swab positive on day 1 compared to household contacts swab negative on day 1, during the study period as measured with daily symptom diary until on day 28|Number of participants with clinical symptoms of neurological long COVID at 6 months post initial positive COVID-19 test.|Number of participants with clinical symptoms of neurological long COVID at 12 months post initial positive COVID-19 test.
NCT04402892 COVID-19: SARS-CoV-2 Specific Memory B and T-CD4+ Cells Not yet recruiting Not Applicable Jun/01/2020 Mar/01/2021
  • Alternative id - APHP200551
  • Interventions - Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients )|Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Immunological memory: resolution of COVID-19 after SARS-CoV2 infection.
NCT04505774 Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE Recruiting Phase 4 Sep/04/2020 Dec/01/2022
  • Alternative id - ACTIV-4 ACUTE|1OT2HL156812-01
  • Interventions - Drug: theraputic heparin|Drug: prophylactic heparin|Drug: P2Y12|Drug: Crizanlizumab Injection|Drug: SGLT2 inhibitor
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Alabama, Birmingham, Alabama, United States|University of Arizona, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente Fontana, Fontana, California, United States|Kaiser Permanente Los Angeles, Los Angeles, California, United States|Smidt Heart Institute at Cedars-Sinai, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC San Diego Hillcrest, San Diego, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|UCSF San Francisco, San Francisco, California, United States|Zuckerberg San Francisco General Hospital, San Francisco, California, United States|Stanford University Medical Center, Stanford, California, United States|Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|St. Mary's Hospital & Regional Medical Center, Grand Junction, Colorado, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|University of Florida, Gainesville, Florida, United States|Memorial Hospital, Jacksonville, Florida, United States|AdventHealth Tampa, Tampa, Florida, United States|Emory, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Queens Medical Center, Honolulu, Hawaii, United States|Memorial Hospital, Belleville, Illinois, United States|Cook County Health, Chicago, Illinois, United States|University of Illinois at Chicago Health (UIH), Chicago, Illinois, United States|OSF Little Company of Mary Medical Center (OSF LCM), Evergreen Park, Illinois, United States|Indiana University Health Methodist Hospital, Indianapolis, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|St Elizabeth's Medical Center, Brighton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School of Medicine, ACCS Research, Saint Louis, Missouri, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Cooper Health, Camden, New Jersey, United States|Englewood Health, Englewood, New Jersey, United States|Atlantic Health System, Morristown, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|AtlantiCare Regional Medical Center, Pomona, New Jersey, United States|Albany Medical College, Albany, New York, United States|Jacobi Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mercy Hospital Buffalo, Buffalo, New York, United States|VA New York Harbor Healthcare System, New York, New York, United States|NYU Langone, New York, New York, United States|Mt. Sinai Hospital, New York, New York, United States|SUNY Upstate University Hospital, Syracuse, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest, Winston-Salem, North Carolina, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|The MetroHealth System, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State Universtiy Wexner Medical Center, Columbus, Ohio, United States|Mercy Health St Vincent Medical Center, Toledo, Ohio, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Research, Danville, Pennsylvania, United States|Doylestown Cardiology Associates, Doylestown, Pennsylvania, United States|Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States|UPMC Presbyterian, Pittsburgh, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Sarah Cannon and HCA Research Institute, Nashville, Tennessee, United States|Skyline Medical Center, Nashville, Tennessee, United States|University of Texas at Austin, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Medical City Ft Worth, Fort Worth, Texas, United States|Baylor Scott and White Medical Center - Temple, Temple, Texas, United States|HCA Henrico Doctors Hospital, Richmond, Virginia, United States|Swedish Hospital, Seattle, Washington, United States|West Virginia University CTR, Morgantown, West Virginia, United States|University of Wisconsin Hospital; Meriter Hospital (UW affiliated), Madison, Wisconsin, United States|Hospital Universitario Sao Francisco de Assis, Braganca Paulista, Brazil|União Brasileira de Educação e Assistência - Hospital São Lucas da PUCRS, Porto Alegre, Brazil|Centro de Estudos Clínicos do Hospital Cárdio Pulmonar, Salvador, Brazil|Fundação Faculdade Regional De Medicina De São José Do Rio Preto, São José do Rio Preto, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP-InCor-HCFMUSP, São Paulo, Brazil|Azienda Ospedaliero Sant Anna e San Sebastiano, Caserta, Italy|Maria Cecilia Hospital , Cotignola, Ravenna, Cotignola, Italy|Università degli Studi di Ferrara, Ferrara, Ferrara, Italy|Azienda Ospedaliero -Universitaria Careggi, Firenze, Italy|Policlinico di Napoli, Napoli, Napoli, Italy|AOU Policlinico di Palermo, Palermo, Palermo, Italy|ASL-1 Imperiese, Sanremo, Sanremo, Italy|Hospital Universitario A Coruna, A Coruna, Spain|Hospital Virgen del Mar, Almeria, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - 21 Day Organ Support (respiratory or vasopressor) Free Days|Secondary Endpoint all cause mortality|Other Platform Secondary Endpoints of Morbidity and Hospitalization|Days free of death|Death Composite|Acute kidney injury
NCT04372589 Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) Completed Phase 2|Phase 3 May/20/2020 May/17/2021
  • Alternative id - ATTACC|OZM-113
  • Interventions - Drug: Heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Emory University Hospital Midtown, Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic, Jefferson, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Henry Ford University, Dearborn, Michigan, United States|Beaumont Hospital, Royal Oak, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Saint Louis University School of Medicine/Saint Louis Veterans Affairs Medical Center, Saint Louis, Missouri, United States|Cooper University Health Care, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Barnabas Medical Center, Livingston, New Jersey, United States|Montefiore-Einstein Center for Heart and Vascular Care, New York, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Santa Casa de Misericordia de Itabuna, Itabuna, BA, Brazil|Hospital Unimed do Cariri, Juazeiro do Norte, CE, Brazil|Instituto Goiano de Oncologia e Hematologia - INGOH, Goiania, Goias, Brazil|Centro de Pesquisas Clínicas Humap - UFMS, Campo Grande, Mato Grosso Do Sul, Brazil|Hospital Felício Rocho, Belo Horizonte, MG, Brazil|Clinica de Campo Grande S/A, Campo Grande, MS, Brazil|Unimed Campo Grande, Campo Grande, MS, Brazil|Hospital Agamenon Magalhaes, Recife, Pernanbuco, Brazil|Hospital das Clinicas da UFPR, Curitiba, PR, Brazil|Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil|Parana Medical Research Center, Maringa, PR, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Universitario Pedro Ernesto, Rio de Janeiro, RJ, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Instituto de Cardiologia do Rio Grande do Sul, Porto Alegre, RS, Brazil|Instituto de Medicina Vascular, Porto Alegre, RS, Brazil|AngioCor Blumenau, Blumenau, Santa Catarina, Brazil|Instituto de Cardiologia de Santa Catarina, Sao Jose, Santa Catarina, Brazil|Instituto de Pesquisa Clínica de Campinas, Campinas, Sao Paulo, Brazil|Praxis Pesquisa Medica, Santo Andre, Sao Paulo, Brazil|Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil|Casa de Saúde Santa Marcelina, Sao Paulo, SP, Brazil|Instituto de Molestias Cardio Vasculares de Tatui, Tatui, SP, Brazil|Hospital 9 de Julho, São Paulo, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Instituto de Infectologia Emilio Ribas, São Paulo, Brazil|Instituto do Coração do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente Israelita Hospital Albert Einstein, São Paulo, Brazil|Victoria General Hospital, Victoria, British Columbia, Canada|Health Sciences Center Winnipeg, Winnipeg, Manitoba, Canada|Grace General Hospital, Winnipeg, Manitoba, Canada|St. Boniface General Hospital, Winnipeg, Manitoba, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|Hôpital Montfort, Ottawa, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier de l'université de Montréal (CHUM), Montréal, Quebec, Canada|Jewish General Hospital, Montréal, Quebec, Canada|CHU de Quebec-University Laval, Québec, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Québec (CRIUCPQ), Québec, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada|Hospital de Infectolog´ñia Centro Médico Nacional La Raza, Azcapotzalco, Mexico City, Mexico|Hospital General Regional 1 Carlos MacGregor Sánchez Navarro, Benito Juárez, Mexico City, Mexico|Hospital General regional 2 El Marqués, Querétaro, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1200
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality and days free of organ support|Arterial and venous thrombotic conditions|Intubation and mortality|All-cause mortality|Intubation|Hospital-free days|Ventilator-free days|Myocardial infarction|Ischaemic stroke|Venous thromboembolism|Vasopressor-free days|Renal replacement free days|Hospital re-admission|Acute kidney injury|Systemic arterial thrombosis or embolism|ECMO support|Mechanical circuit thrombosis|WHO ordinal scale|Major bleeding|Heparin-induced thrombocytopenia (HIT)
NCT04842292 Nebulized Heparin for COVID19-associated Acute Respiratory Failure Recruiting Phase 2 May/20/2021 Mar/31/2022
  • Alternative id - 65139
  • Interventions - Drug: Heparin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - UK Healthcare, Lexington, Kentucky, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Mean PaO2/FiO2 ratio|Clinically Significant Bleeding|Incidence of venous thromboembolism
NCT04990830 Effects of Low Molecular Weight Heparin Therapy With Soft-Mist Inhaler for COVID-19 Induced Hypoxemia Completed Phase 2|Phase 3 Feb/03/2021 May/21/2021
  • Alternative id - E-66175679-514.03.01-328141|46325
  • Interventions - Drug: Inhaled Low molecular weight heparin|Drug: Standard Treatment
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Istanbul University Medical Faculty, Istanbul, Fatih, Turkey
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 80
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in clinical status on a 5-point clinical scale for hypoxemia|Improvement rate of the breathing status|Change in peripheral oxygen saturation (Sp02)|Length of stay|Overall survival
NCT04787510 COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection Completed Dec/23/2020 Jun/23/2021
  • Alternative id - 895/23-12-2020
  • Interventions - Drug: low molecular weight Heparin as standard of care treatment
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University General Hospital of Ioannina, Ioánnina, Epirus, Greece
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - EFFECT OF COVID-19 DISEASE IN CLOTTING FACTORS
NCT04545541 Nebulised Heparin in Patients With Severe COVID-19 Recruiting Phase 2|Phase 3 Nov/01/2020 Jun/01/2022
  • Alternative id - CHARTER meta-trial
  • Interventions - Drug: Nebulised unfractionated heparin (UFH)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Frederick Health Hospital, Frederick, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Alive and Ventilator Free Score
NCT04723563 Nebulized Heparin for the Treatment of COVID-19 Completed Phase 4 Feb/22/2021 Aug/23/2021
  • Alternative id - FHHep2121
  • Interventions - Drug: Heparin|Drug: 0.9%sodium chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Frederick Health Hospital, Frederick, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Need for mechanical ventilation at day 28|Hospital length of stay|Average daily SaO2/FiO2
NCT04393805 Heparins for Thromboprophylaxis in COVID-19 Patients: HETHICO Study in Veneto Completed Jun/01/2020 Feb/26/2021
  • Alternative id - HETHICO
  • Interventions - Drug: Low Molecular Weight Heparin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Giuseppe Camporese, Padova, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 744
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Bleeding|Thrombosis|Mortality|Worsening|LOS
NCT04640181 Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT) Completed Phase 2 Dec/01/2020 Jun/28/2021
  • Alternative id - 2020-001708-41
  • Interventions - Drug: Enoxaparin|Drug: Rivaroxaban
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St. David's Medical Center, Austin, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Death or 30-day all cause mortality|Mechanical ventilation, intubation|Transfer to an ICU setting|New requirement for hemodialysis (HD) or continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO)|New thrombotic events|Major bleeding event|Time to recovery (defined as no limitation or minor limitation in activity level or hospitalized but require no oxygen)
NCT04487990 CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19 Active, not recruiting Not Applicable Jun/29/2020 Aug/01/2021
  • Alternative id - U1111-1252-0194|33351120.0.0000.0068
  • Interventions - Drug: unfractionated Heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of São Paulo General Hospital, São Paulo, SP, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 118
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clotted dialyzers|Time-free of clotting|Number of dialyzers used|Pressure variation|Urea sieving|Downtime of dialysis
NCT05256524 Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin? Completed Mar/01/2020 Aug/29/2021
  • Alternative id - AntiFactorXa in Covid-19
  • Interventions - Drug: The effect of LMWH|Diagnostic Test: Monitoring frequency of aFXa-levels
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Södersjukhuset, Stockholm, Sweden
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 1520
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mortality|Thromboembolic events|Bleeding events
NCT04394377 Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial Completed Phase 4 Jun/21/2020 May/30/2021
  • Alternative id - 002/2020
  • Interventions - Drug: Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|Drug: Group 2: control group with enoxaparin 40mg/d
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Centro de Estudos Clínicos do Hospital Cárdio Pulmonar, Salvador, Bahia, Brazil|Instituto de Ensino e Pesquisa do Hospital da Bahia, Salvador, Bahia, Brazil|Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel, Salvador, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Centro de Ensino e Aperfeiçoamento em Pesquisa - CEAP, Serra, Espirito Santo, Brazil|Centro de Pesquisas Cardiológicas de Goiânia do Hospital das Clínicas (UFG), Goiânia, Goiás, Brazil|Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Núcleo de Ciências de Saúde - Unidade de Pesquisa - Hospital Felício Rocho, Belo Horizonte, Minas Gerais, Brazil|Centro de Pesquisa Clínica do Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil|Hospital Universitário da Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Agamenon Magalhães, Recife, Pernambuco, Brazil|Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nereu Ramos, Florianópolis, Santa Catarina, Brazil|Instituto Baia Sul de Ensino E Pesquisa Dr. Irineu May Brodbeck / Hospital Baía Sul, Florianópolis, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Hospital de Amor de Barretos - (Pio XII), Barretos, São Paulo, Brazil|Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - Unesp, Botucatu, São Paulo, Brazil|Hospital Universitário São Francisco de Assis, Bragança Paulista, São Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, São Paulo, Brazil|Hospital Regional de Registro, Registro, São Paulo, Brazil|Praxis Pesquisa Médica, Santo André, São Paulo, Brazil|Centro Integrado de Pesquisa (CIP) - Hospital de Base de Rio Preto, São José Do Rio Preto, São Paulo, Brazil|Hospital Regional de São José dos Campos, São José Dos Campos, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, Brazil|BP - A Beneficência Portuguesa de São Paulo, São Paulo, Brazil|Hcor - Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano Paulista, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Paulo, São Paulo, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil|Instituto de Assistência Médica ao Servidor Público Estadual de S. Paulo, São Paulo, Brazil|Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da USP-InCor-HCFMUSP, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 615
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hierarchical composite endpoint composed of mortality, number of days alive, number of days in the hospital and number of days with oxygen therapy at the end of 30 days.|Incidence of Venous thromboembolism|Incidence of acute myocardial infarction|Incidence of stroke|Number of days using oxygen therapy|Peak of troponin|Peak of D-dimer|Incidence of Major bleeding and clinically relevant non-major bleeding by the ISTH criteria
NCT04466670 Hemostasis in COVID-19: an Adaptive Clinical Trial Recruiting Phase 2 Jul/11/2020 May/30/2022
  • Alternative id - 33788820.9.0000.0068
  • Interventions - Drug: acetylsalicylic acid|Drug: Unfractionated heparin nebulized
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Vanderson Rocha, Sao Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 379
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital discharge - alive / death|Length of mechanical ventilation free days|Length of renal replacement therapy free days|Number of documented venous thromboembolism or arterial thrombosis
NCT05184101 Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19) Not yet recruiting Phase 2|Phase 3 May/01/2022 Apr/01/2023
  • Alternative id - INHALE-HEP Australia Version 3
  • Interventions - Drug: unfractionated Heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 100
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Intubation|Mortality|Oxygenation
NCT04401293 Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients Completed Phase 3 Apr/26/2020 May/14/2021
  • Alternative id - 20-0340
  • Interventions - Drug: Enoxaparin|Drug: Prophylactic/Intermediate Dose Enoxaparin
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Beth Israel Newark, Newark, New Jersey, United States|Southside Hospital, Bay Shore, New York, United States|Huntington Hospital, Huntington, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States|Staten Island University Hospital, Staten Island, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 257
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days.|Major Bleeding|Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Hospital Day 10 + 4|Sepsis-induced Coagulopathy (SIC) Score|Progression to Acute Respiratory Distress Syndrome (ARDS)|Need for Intubation|Re-hospitalization
NCT04542408 Hamburg Edoxaban for Anticoagulation in COVID-19 Study Recruiting Phase 3 Nov/12/2020 Sep/01/2022
  • Alternative id - HERO-19
  • Interventions - Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)|Drug: Low dose Low molecular weight heparin or Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - UK Aachen, Aachen, Germany|Universitätsklinikum Augsburg, Augsburg, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitärsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hanover, Germany|TU München Klinikum rechts der Isar, München, Germany
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 172
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Combined endpoint: all-cause mortality and/ or venous thromboem-bolism and/ or arterial thromboembolism|All-cause mortality|Mortality related to venous thromboembolism|Mortality related to arterial thromboembolism|Rate of venous and/ or arterial thromboembolism|Rate and length of mechanical ventilation|Length of initial stay at ICU after application of IMP|Rehospitalisation|Rate and length of renal replacement therapy|Cardiac arrest/ CPR
NCT04380818 Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 Recruiting Not Applicable Jun/05/2020 Nov/01/2021
  • Alternative id - IPACOVID
  • Interventions - Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain
  • Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 106
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1
NCT04584580 D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia Recruiting Phase 4 Aug/01/2020 Dec/31/2020
  • Alternative id - FMASU P35/ 2020
  • Interventions - Drug: low-molecular-weight heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - mortality|occurrence of venous and/or arterial thrombosis|occurrence of Sepsis-induced coagulopathy|Occurrence of adult respiratory distress syndrome (ARDS)|Occurrence of sepsis|ICU admission and need for mechanical ventilation
NCT04397510 Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury Enrolling by invitation Phase 4 Jun/01/2020 Dec/31/2021
  • Alternative id - FHHep518
  • Interventions - Drug: Heparin|Drug: 0.9% Sodium-chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Frederick Health Hospital, Frederick, Maryland, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Mean daily PaO2 to FiO2 ratio|Duration of mechanical ventilation|ICU length of stay|Mortality Rate|Incidence of adverse drug events
NCT04530578 Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19 Recruiting Phase 4 Jun/01/2020 Jun/01/2021
  • Alternative id - CSanCamilo
  • Interventions - Drug: Heparin sodium|Drug: Enoxaparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 200
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Percentage of patients requirement mechanical ventilation|Percentage of patients with PaO2 to Fi02 ratio > 300|Lengths of hospital-stay|Mortality rate
NCT04528888 Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Recruiting Phase 3 Nov/25/2020 Jul/30/2021
  • Alternative id - Staunch-19-1.1-26-04-20
  • Interventions - Drug: Enoxaparin|Drug: Methylprednisolone|Drug: unfractionated heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ICU- University Hospital Modena, Modena, Italy
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 210
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - All-cause mortality at day 28|All-cause mortality at ICU discharge|All-cause mortality at hospital discharge|Need of rescue administration of high-dose steroids or immune-modulatory drugs|New organ dysfunction during ICU stay|Grade of organ dysfunction during ICU stay|ICU free days at day 28|Occurrence of new infections|Ventilation free days at day 28|Vasopressors free-days at day 28|Switch from non-invasive to invasive mechanical ventilation|Delay from start of non-invasive ventilation to switch to invasive ventilation|Occurrence of protocol related adverse events|Occurrence of venous thromboembolism, stroke or myocardial infarction|Occurrence of major bleeding (safety end point)|Occurrence of clinically relevant non-major bleeding (safety end point)
NCT04635241 Inhaled Heparin for Hospitalised COVID-19 Patients Recruiting Phase 2|Phase 3 Jun/01/2020 Dec/01/2022
  • Alternative id - INHALE-HEP meta-trial
  • Interventions - Drug: Unfractionated heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - San Camilo Clinic, Buenos Aires, Argentina|15th May hospital, Cairo, Egypt
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 712
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Intubation rate|WHO ordinal scale COVID19|Oxygenation
NCT04600141 Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection Completed Phase 3 Nov/10/2020 Dec/31/2021
  • Alternative id - HEPMAB
  • Interventions - Drug: Tocilizumab|Drug: Heparin - Therapeutic dosage|Drug: Heparin - Prophylactic dosage
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Fundação São Francisco Xavier, Ipatinga, Minas Gerais, Brazil|UNIMED Varginha, Varginha, Minas Gerais, Brazil|Universidade Federal de Sergipe, Aracaju, Sergipe, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 308
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with clinical improvement|Hospital and ICU length of stay;|Duration of invasive mechanical ventilation|Duration of vasopressor use|Renal failure by AKIN criteria|Incidence of cardiovascular complications|Incidence of venous thromboembolism|Mortality
NCT04485429 Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia Withdrawn Phase 3 Jul/20/2020 Dec/31/2022
  • Alternative id - 31180820600005249
  • Interventions - Drug: Methylprednisolone|Drug: Heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - D'Or Institute for Research and Education, Rio de Janeiro, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of invasive mechanical ventilation|Severity assessment by ordinal severity scale|Severity assessment by SOFA score|Length of hospital stay|Length of stay in intensive care|Death rate
NCT04492254 Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients Recruiting Phase 3 Sep/15/2020 Sep/01/2021
  • Alternative id - TRI-08892|2020-003125-39
  • Interventions - Drug: Enoxaparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Harry Gibbs, National Co-ordinating Investigator, The Alfred Hospital, Melbourne, Australia|Dr Frank Cools, National Co-ordinating Investigator, AZ Klina, Brasschaat, Belgium|Prof. Barry Jacobson, National Coordinating Investigator, University of the Witwatersrand, Johannesburg, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1370
  • Age - 55 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital Admission|Death|Bleeding (as defined by ISTH criteria)|Diagnosis of VTE
NCT04486508 Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 Completed Phase 3 Jul/30/2020 Jul/05/2021
  • Alternative id - 99060
  • Interventions - Drug: intermediate dose Enoxaparin/ unfractionated heparin|Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin|Drug: Atorvastatin 20mg|Drug: Matched placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Masih Daneshvari Hospital, Tehran, Iran, Islamic Republic of
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - a composite of acute VTE, arterial thrombosis, treatment with ECMO, or all-cause mortality|Rate of all-cause mortality|Rate of objectively-confirmed VTE|Ventilator free days|Rate of major bleeding|Rate of clinically-relevant non-major bleeding|Rate of severe thrombocytopenia|Rate of rise in liver enzymes|Clinically-diagnosed myopathy|Objectively-confirmed arterial thrombosis
NCT04406389 Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial) Recruiting Phase 4 Oct/13/2020 Dec/01/2022
  • Alternative id - 20-04021936
  • Interventions - Drug: Enoxaparin sodium|Drug: Unfractionated heparin|Drug: Fondapariniux|Drug: Argatroban
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Weill Cornell Medicine, New York, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 186
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - 30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events
NCT04367831 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19 Completed Phase 4 May/02/2020 May/12/2021
  • Alternative id - AAAS8980
  • Interventions - Drug: Enoxaparin Prophylactic Dose|Drug: Heparin Infusion|Drug: Heparin SC|Drug: Enoxaparin/Lovenox Intermediate Dose
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Columbia University Medical Center, New York, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 94
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Total Number of Patients with Clinically Relevant Venous or Arterial Thrombotic Events in ICU|Total Number of Patients with In hospital Clinically Relevant Venous or Arterial Thrombotic Events|ICU Length of Stay|Total Number of Patients with the Need for Renal Replacement Therapy in the ICU|Total Number of Patients with Major bleeding in the ICU|Hospital Length of Stay
NCT04743011 Enriched Heparin Anti COVID-19 Trial Recruiting Phase 1|Phase 2 Jun/01/2021 Dec/31/2021
  • Alternative id - UPECLIN-MB-2
  • Interventions - Drug: Heparin sodium|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital das Clinicas de Boucatu, Botucatu, Sao Paulo, Brazil|School of Medicine at Botucatu- Paulista State University- UNESP, São Paulo, Brazil, Botucatu, SP, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in activated partial thromboplastin time (APTT) > 1.5|Viral load in nasal swab reverse transcription polymerase chain reaction (RT-PCR).|Number of participants needing supplemental oxygen therapy|Number of participants needing mechanical pulmonary ventilation|Number of hospitalization days|Number of participants that develop renal failure|Number of participants that develop major cardiovascular events|Number of participants transferred to the intensive care unit (ICU)|Number of participants presenting secondary pulmonary bacterial infections|Number of participants that develop deep vein thrombosis (DVT)|Number of participants that develop pancreatitis|Number of participants that need corticosteroid therapy|Number of deaths among participants|Number of participants with increased white blood cell count|Number of participants with increased C reactive protein test|Number of participants with deterioration of arterial blood gas paO2/pFiO2 ratio|Number of participants with altered sodium|Number of participants with altered potassium|Number of participants with increased pulmonary area compromised (%)
NCT05279391 Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19 Recruiting Not Applicable Oct/25/2020 Dec/31/2023
  • Alternative id - 87/08-04-2020|16210/20-04-2021
  • Interventions - Drug: Dexamethasone|Drug: Low molecular weight heparin|Drug: Anakinra 100Mg/0.67Ml Inj Syringe|Drug: Tocilizumab|Drug: Baricitinib|Drug: Dornase Alfa Inhalant Product
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University Hospital of Alexandroupolis, Alexandroupolis, Evros, Greece
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - In-hospital mortality rate|Intubation rate|Days of hospitalization|Overall mortality rate
NCT04655586 Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 Completed Phase 2|Phase 3 Dec/10/2020 Jan/19/2022
  • Alternative id - NAPc-201/301
  • Interventions - Drug: rNAPc2|Drug: Heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ARCA Investigational Site #119, Fairhope, Alabama, United States|ARCA Investigational Site #118, Phoenix, Arizona, United States|ARCA Investigational Site #120, Tucson, Arizona, United States|ARCA Investigational Site #104, Aurora, Colorado, United States|ARCA Investigational Site #117, Denver, Colorado, United States|ARCA Investigational Site #101, Jacksonville, Florida, United States|ARCA Investigational Site #128, Evanston, Illinois, United States|ARCA Investigational Site #113, New Orleans, Louisiana, United States|ARCA Investigational Site #105, Falls Church, Virginia, United States|ARCA Investigational Site #114, Richmond, Virginia, United States|ARCA Investigational Site #103, Tacoma, Washington, United States|ARCA Investigational Site #127, San Nicolás, Buenos Aires, Argentina|ARCA Investigational Site #130, Rosario, Santa Fe, Argentina|ARCA Investigational Site #112, Rosario, Sante Fe, Argentina|ARCA Investigational Site #111, Buenos Aires, Argentina|ARCA Investigational Site #115, Caba, Argentina|ARCA Investigational Site #126, Cordoba, Argentina|ARCA Investigational Site #129, San Miguel de Tucuman, Argentina|ARCA Investigational Site #106, San Miguel De Tucumán, Argentina|ARCA Investigational Site #125, Campo Grande, Mato Grosso Do Sul, Brazil|ARCA Investigational Site #124, Braganca Paulista, Sao Paolo, Brazil|ARCA Investigational Site #122, Sao Jose do Rio Preto, Sao Paolo, Brazil|ARCA Investigational Site #123, Porto Alegre, Brazil|ARCA Investigational Site #121, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 160
  • Age - 18 Years to 90 Years   (Adult, Older Adult)
  • Outcome measures - Change in D-dimer level from Baseline to Day 8, or day of discharge if prior to Day 8 (Phase 2b)|Number of major or non-major clinically relevant bleeding events within eight (8) days of randomization as compared to heparin (Phase 2b and 3)|Time to recovery within thirty (30) days of randomization using the ACTT ordinal scale (Phase 3)|Change in D-dimer level from baseline to 24 hours post-dose (Day 2) and Day 3 (Phase 2b)|Number of major or non-major clinically relevant bleeding events with rNAPc2 vs. heparin through Day 30 (Phase 2b and 3)|Number of bleeding events in subjects treated with higher vs. lower dose rNAPc2 through Day 30 (Phase 2b)|Time to first occurrence of a composite of thrombotic events and all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Time to first occurrence of thrombotic events within thirty (30) days of randomization (Phase 3 only)|Time to all-cause mortality within thirty (30) days of randomization (Phase 3 only)|Change in Tissue Factor laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b)|Change in interleukin-6 laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b)|Change in high sensitivity C-reactive protein laboratory values in rNAPc2 treated subjects who had clinical events related to coagulation and inflammation from baseline through Day 8 (Phase 2b)
NCT04668404 Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19 Recruiting Aug/24/2020 Feb/01/2021
  • Alternative id - IEC-04/2020-1641
  • Interventions - Diagnostic Test: Sonoclot
  • Study type - Observational
  • Study results - No Results Available
  • Locations - PGIMER, Chandigarh, India
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 50
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Correlation of of conventional coagulation tests with point of care coagulation test using sonoclot in COVID-19 patients.|Clinical Evidence of thrombosis|Coagulation-related Bleeding Event|Presence of Endogenous Heparinoids as demonstrated on POC test [ Time Frame 0, 3 days]|Intensive care admission duration|28 day mortality
NCT04344756 Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Not yet recruiting Phase 2 Apr/20/2020 Sep/30/2020
  • Alternative id - APHP200389-6
  • Interventions - Drug: Tinzaparin or unfractionated heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France|réanimation hôpital Cochin, Paris, France|Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 808
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Survival without ventilation (VNI or mechanical ventilation)|ventilator free survival|World Health Organisation(WHO) progression scale ≤5|World Health Organisation(WHO) progression scale|overall survival|Length of hospital stay|Length of ICU stay|time to oxygenation supply independency|time to ventilator (non invasive or invasive)|rate of acute kidney injury|time to Renal Replacement Therapy (RRT) initiation|rate of clinically overt pulmonary embolism or proximal deep vein thrombosis|Rate of clinically overt arterial thrombosis|Rate of unscheduled central venous catheter replacement for catheter dysfunction|Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)|Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction|Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not|Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system|Incidence of adverse events
NCT04373707 Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 Completed Phase 4 May/13/2020 Sep/14/2021
  • Alternative id - 2020-001709-21
  • Interventions - Drug: Enoxaparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Amiens Academic Hospital, Amiens, France|Besançon Academic Hospital, Besançon, France|Brest Academic Hospital, Brest, France|Civil Hospital, Colmar, France|Dijon Academic Hospital, Dijon, France|Kremlin Bicêtre Academic Hospital, Le Kremlin-Bicêtre, France|Lille Academic Hospital, Lille, France|Groupe Hospitalier Unéos, Metz, France|Metz-Thionville Regional Hospital, Metz, France|Montpellier Academic Hospital, Montpellier, France|Emile Muller Hospital, Mulhouse, France|Nancy Academic Hospital, Nancy, France|George Pompidou European Hospital, Paris, France|Lariboisière Academic Hospital, Paris, France|St Etienne Academic Hospital, Saint-Étienne, France|Strasbourg Academic Hospital, Strasbourg, France|Toulouse Academic Hospital, Toulouse, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 1000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Venous thromboembolism|Major bleeding|Major Bleeding and Clinically Relevant Non-Major Bleeding|Net Clinical Benefit|Venous Thromboembolism at other sites|Arterial Thrombosis|All-Cause Mortality|Factors associated with the risk of venous thromboembolism
NCT04359212 Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 Completed May/01/2020 Jul/31/2020
  • Alternative id - VTE-COVID
  • Interventions - Drug: thromboprophylaxis with low-molecular-weight heparin or fondaparinux
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Giuseppe Camporese, Padova, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 90
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism|the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism
NCT05224388 Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels. Recruiting Jan/01/2020 Mar/30/2022
  • Alternative id - BC-07991
  • Interventions - Drug: Enoxaparin|Drug: Heparin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Ghent University Hospital, Gent, Belgium
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 800
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Evaluate dose regimen of UFH en LMWH for critically ill patients and Covid-19 patients in: - preventing thrombo-embolic complications - time to reach adequate prophylactic antiXa range|Possible risk factors for thrombo-embolic complications in COVID-19 patients|Safety of increased dose of thromboprophylaxis in Covid-19 patients
NCT04511923 Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury Recruiting Phase 1|Phase 2 Dec/23/2020 Jan/01/2022
  • Alternative id - NUIG-2020-003
  • Interventions - Drug: Nebulised heparin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University Hospital Galway, Galway, Ireland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 40
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - D-dimer profile|Frequenccy of Severe Adverse Outcomes|Oxygenation Index|Indices of Inflammation|Ratios of Indices of Inflammation|Indices of Coagulation|Quasi-Static Lung Compliance|Time to separation from advanced respiratory support|Number treated with neuromuscular blockers|Number treated with Prone positioning|Number treated with extra-corporeal membrane oxygenation|Number requiring Tracheostomy|Time to separation from invasive ventilation among survivors|Discharge to ward|Discharge to ward in survivors|Patient Survival|Number of patients residing at home or in a community setting at day 60|Number of surviving patients residing at home or in a community|Ventilatory ratio|Number treated with awake prone positioning
NCT04490239 Intranasal Heparin Tolerability Study Completed Early Phase 1 Oct/09/2020 Nov/18/2020
  • Alternative id - Intranasal Heparin
  • Interventions - Drug: Intranasal heparin sodium (porcine)
  • Study type - Interventional
  • Study results - Has Results
  • Locations - The University of Mississippi National Center for Natural Products Research, University, Mississippi, United States
  • Study designs - Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 6
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 1|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Acute Phase Day 2|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 14|Number of Participants With Normal or Abnormal Activated Partial Thromboplastin Time (aPTT), Chronic Phase Day 15|Percent Change in Platelet Count From Pre-dose Baseline|Number of Incidents of Epistaxis, Acute Phase|Number of Incidents of Epistaxis, Chronic Phase|Number of Participants With Normal or Abnormal Platelet Counts, Chronic Phase Day 14|Other Adverse Effects, Acute Phase|Other Adverse Effects, Chronic Phase
NCT04394182 Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 Recruiting Not Applicable Apr/21/2020 Apr/21/2021
  • Alternative id - 20.4.1597-GHM
  • Interventions - Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 15
  • Age - 18 Years to 120 Years   (Adult, Older Adult)
  • Outcome measures - Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity
NCT04409834 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Recruiting Phase 4 Aug/05/2020 Mar/01/2022
  • Alternative id - CCCTN/TIMI COVID-PACT
  • Interventions - Drug: Unfractionated Heparin IV|Drug: Enoxaparin 1 mg/kg|Drug: Clopidogrel|Drug: Unfractionated heparin SC|Drug: Enoxaparin 40 Mg/0.4 mL Injectable Solution
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Brigham and Women's Hospital, Boston, Massachusetts, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  • Enrollment - 750
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Primary endpoint: Venous or arterial thrombotic events|Key secondary endpoint: Clinically evident venous or arterial thrombotic events
NCT04355728 Use of UC-MSCs for COVID-19 Patients Completed Phase 1|Phase 2 Apr/25/2020 Oct/31/2020
  • Alternative id - 20200671|20200370
  • Interventions - Biological: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.|Other: Vehicle + Heparin along with best supportive care
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 24
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Pre-Specified Infusion Associated Adverse Events|Number of Subjects With Serious Adverse Events by 31 Days After First Infusion|Percentage of Participants Experiencing Serious Adverse Events (SAEs) Through Study Day 90|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Adverse Events (AEs) and Serious Adverse Events (SAEs) by Severity|Subjects With Adverse Events and Serious Adverse Events by Severity|Number of Adverse Events and Serious Adverse Events by Relatedness to Treatment|Subjects With Adverse Events by Relatedness to Treatment|Survival at 31 Days Post First Infusion|Survival at 60 Days Post First Infusion|Time to Recovery|Ventilator-Free Days Throughout 28 Days Post Second Infusion|Ventilator-Free Days Throughout 90 Days|Respiratory Rate and Oxygenation Index (ROX Index)|Oxygenation Index (OI)|Positive End-Expiratory Pressure (PEEP) and Plateau Pressure (Pplat)|Sequential Organ Failure Assessment (SOFA) Scores|Smell Identification Test (SIT) Scores|White Blood Cell Count (WBC)|Platelets Count|Hemogoblin|Hematocrit|Neutrophils|Lymphocytes|Glomerular Filtration Rate|Total Protein|Sodium|Potassium|Creatinine|Glucose|Albumin|Alkaline Phosphatase|Alanine Aminotransferase or Serum Glutamate-pyruvate Transaminase (ALT or SGPT)|Aspartate Aminotransferase or Serum Glutamic Oxaloacetic Transaminase (AST or SGOT)|Total Bilirubin|Blood Urea Nitrogen (BUN)|Calcium|Chloride|Carbon Dioxide (CO2)|C-Reactive Protein Levels|Arachidonic Acid/Eicosapentaenoic Acid (AA/EPA) Ratio|D-dimer Levels|25-Hydroxy Vitamin D Levels|Tumor Necrosis Factor-alpha (TNFα)|Tumor Necrosis Factor-beta (TNFβ)|Soluble Tumor Necrosis Factor Receptor 2 (sTNFR2)|Viral Load by SARS-CoV-2 RT-PCR|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 3 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 6 Post First Infusion|Number of Participants Reporting Panel Reactive Antibody (PRA) Positivity at Day 14 Post First Infusion|Number of Participants With Positive, Negative, or Borderline Serology Testing for SARS-CoV-2 IgM/IgG
Export (.csv)